Welcome to the e-CCO Library!

P584: Efficacy, safety, and tolerability of AMT-101, a gut selective oral IL-10 fusion, in the Phase 2 FILLMORE trial of patients with chronic pouchitis
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Jairath, V.(1)*;Bressler , B.(2);Silverberg , M.S.(3);Lee, L.Y.(4);Lugo, K.A.(4);Mayoral Monibas, R.(4);Annamalai, T.(4);Whitney, J.A.(4);Weng, E.Y.(4);Kanwar, B.(4);Danese , S.(5);Feagan, B.(1);
Created: Friday, 14 July 2023, 11:05 AM
P584: Mucosal Eosinophilia is an Independent Predictor of Vedolizumab Effectiveness in Ulcerative Colitis
Year: 2021
Source: ECCO'21 Virtual
Authors: Gremida, A.(1);Huang, K.(1);Ciorba, M.(1);Deyali , C.(1);Deepak, P.(1);
Created: Wednesday, 2 June 2021, 4:12 PM
P584: Rare and severe complications in children with paediatric-onset IBD; the international PIBD SETQuality Safety Registry by PIBDnet
Year: 2018
Source: ECCO '18 Vienna
Authors:

M. Aardoom1*, P. Kemos2, F. Ruemmele3, N. Croft2, L. de Ridder1, on behalf of the PIBD SETQuality consortium and PIBDnet

Created: Thursday, 21 February 2019, 9:14 AM
P584: Systematic Review and Meta-analysis Evaluating the Real-World Effectiveness and Safety of Ustekinumab in Crohn’s Disease
Year: 2022
Source: ECCO'22
Authors: Hosack, T.(1);Gadhok, R.(2);Lindsay, J.O.(2);
Created: Friday, 11 February 2022, 3:56 PM
P585 Evaluation and comparison of the safety profiles of different intravenous iron preparations and oral iron for treatment of iron deficiency anaemia: Preliminary results from the IBD subgroup analysis
Year: 2020
Source:

ECCO'20 Vienna

Authors:

A. Aksan1,2,3, H. Işık4, S. Aksan2, D. Tuğal5, A. Dignass6, J.M. Stein2,3,7

Created: Thursday, 30 January 2020, 10:12 AM
P585: Duration of response to ozanimod after treatment withdrawal: results from the phase 3 True North study
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Vermeire, S.(1)*;Abraham, B.(2);Bressler, B.(3);Reinisch, W.(4);Jain, A.(5);Memaj, A.(5);Akukwe, L.(5);Liu, W.J.(5);Osterman, M.(5);Canavan, J.B.(5);Sands, B.E.(6);
Created: Friday, 14 July 2023, 11:05 AM
P585: Efficacy of iDose dashboard forecast for individualising Infliximab therapy: an Indian experience
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

M. Dave1, A. Dherai1, D. Desai*2, D. Mould3, T. Ashavaid1

Created: Friday, 22 February 2019, 9:41 AM
P585: Examining faecal incontinence and its impact on health-related quality of life in patients with Crohn’s perianal fistulas: results from a multi-country burden of illness study
Year: 2022
Source: ECCO'22
Authors: Karki, C.(1);Athavale, A.(2);Hantsbarger, G.(3);Lee, K.(4);Milicevic, S.(5);Perovic, M.(6);Raven, L.(7);Sajak-Szczerba, M.(8);Sharpe, E.(9);Tozer, P.(10);
Created: Friday, 11 February 2022, 3:56 PM
P585: IBD Reference and Biosimilar adalimumab CroSS over Study (iBaSS): a mixed methods clinical trial of patients transitioning between originator and biosimilar adalimumab. Qualitative findings from an interim analysis presenting the patient perspective.
Year: 2021
Source: ECCO'21 Virtual
Authors: Young, D.(1);Latter, S.(2);Harvey, J.(3);Addison, J.(4);Freudensprung, U.(5);Cummings, F.(1);
Created: Wednesday, 2 June 2021, 4:12 PM
P585: Impact of timing of thiopurine treatment on first intestinal resection in Crohn’s disease with poor prognostic factors: A nationwide population-based cohort study 2004–2015
Year: 2018
Source: ECCO '18 Vienna
Authors:

S.Y. Shin1*, J. Lee2, J.J. Park1, J.H. Cheon3, T.I. Kim3, H. Park1, W.H. Kim3, A.S. Shin2

Created: Thursday, 21 February 2019, 9:14 AM
P585: Infliximab in moderate to severe ulcerative colitis: comparison between scheduled treatment strategy and bridge strategy
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Sambuelli A.*1, Bellicoso M.2, Negreira S.2, Goncalves S.2, Huernos S.2, Chavero P.2, Tirado P.2, Cabanne A.3, Gil A.2

Created: Wednesday, 20 February 2019, 10:36 AM
P586 Higher infliximab and adalimumab trough levels are associated with fistula healing in patients with fistulising perianal Crohn’s disease
Year: 2020
Source:

ECCO'20 Vienna

Authors:

B. GU1, K. Venkatesh2, A.J. Williams3, W. Ng3, C. Corte4, S. Ghaly2, W. Xuan5, S. Paramsothy6, S. Connor3

Created: Thursday, 30 January 2020, 10:12 AM
P586: A novel approach to the implementation of biosimilar infliximab CT-P13 for the treatment of IBD utilising therapeutic drug monitoring: the Edinburgh experience
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Plevris N., Deekae A., Jones G.R., Manship T.A., Noble C.L., Satsangi J., Shand A.G., Arnott I.D., Lees C.W.

Created: Wednesday, 20 February 2019, 10:36 AM
P586: Comparative effectiveness of vedolizumab and ustekinumab as induction therapy in anti-TNF refractory Crohn’s disease: a multi-centre retrospective cohort study
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

T. Townsend*1, V. Razanskaite2, S. Michail1, J. Morgan1, M. Davies1, D. Storey1, C. Watters3, D. Penman3, M. Swaminathan4, J. Sabine3, A. Chapman2, A. Vyas2, I. Reilly4, P. Flanagan3, K. Bodger2, S. Subramanian1

Created: Friday, 22 February 2019, 9:41 AM
P586: Drug-induced lipid changes in patients with Inflammatory Bowel Disease: a single center, prospective study
Year: 2021
Source: ECCO'21 Virtual
Authors: SleutjesAM, J.(1);de Vries, A.C.(1);Roeters van Lennep, J.E.(2);van der Woude, C.J.(1);
Created: Wednesday, 2 June 2021, 4:12 PM
P586: Surgical recurrence in Crohn’s Disease: Can we prevent it?
Year: 2022
Source: ECCO'22
Authors: Botto, I.(1);Serrazina, J.(1);Coelho Rodrigues, I.(1);Fernandes, S.(1);Bernardo, S.(1);Gonçalves, A.R.(1);Moura Santos, P.(1);Valente, A.(1);Correia, L.(1);Tato Marinho, R.(1);
Created: Friday, 11 February 2022, 3:56 PM
P586: Tofacitinib for the induction and maintenance of medically resistant ulcerative colitis
Year: 2018
Source: ECCO '18 Vienna
Authors:

R. Weisshof*, M. Aharoni Golan, D.T. Rubin

Created: Thursday, 21 February 2019, 9:14 AM
P586: Vedolizumab in Mild to Moderate Crohn's Disease Patients Naïve to Biological Therapy: a Multicentric Observational Study
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Dotti, A.Z.(1);Vilela, E.G.(2);Chebli, J.M.F.(3);Chebli, L.A.(4);Magro, D.O.(5);Steinwurz, F.(6);Argollo, M.(7);Carvalho, N.S.(7);Parente, J.M.L.(8);Parra, R.S.(9);Perin, R.L.(10);Flores, C.(11);Morsoletto, E.M.(12);Ferreira, S.D.C.(13);Ludvig, J.C.(14);Kaiser Jr, R.L.(15);Queiroz, N.S.F.(16);Faria, M.A.G.(17);Nicollelli, G.M.(18);Andrade, A.R.(19);KotzeMD- PhD, P.G.(20)*;
Created: Friday, 14 July 2023, 11:05 AM
P587 Adalimumab in pediatric Crohn’s disease: A long-term multi-centre real-world experience
Year: 2020
Source:

ECCO'20 Vienna

Authors:

S. Lawrence1, H. Huynh2, W. El-Matary3, J. DeBruyn4, M. Carroll2, E. Wine2, J. Chan1, K. Jacobson1

Created: Thursday, 30 January 2020, 10:12 AM
P587: Disease severity in the INFLAMMATORY BOWEL DISEASES: Do patients and physicians agree?
Year: 2022
Source: ECCO'22
Authors: Timmer, A.(1);de Sordi, D.(1);Neuser, J.(1);Seibel, K.(1);Hensel, A.(1);Schmidt-Lauber, M.(2);Allgayer, H.(3);Klebl, F.(4);Obermeier, F.(4);Jessen, P.(5);Schnoy, E.(6);Helwig, U.(7);Morgenstern, J.(8);Leifeld, L.(9);Schmidt, S.(9);Meinhardt, C.(10);Maaser, C.(11);Bästlein, E.(12);Bokemeyer, A.(13);Graefe, U.(14);Kühbacher, T.(15);Kaltz, B.(16);Sander, C.(16);Wolfgang, K.(17);
Created: Friday, 11 February 2022, 3:56 PM